All articles by prameela vegi
prameela vegi
Sun Nuclear SunSCAN™ 3D Water Scanning System Receives CE Marking
Faster, Hyper-Accurate Commissioning and Beam Scanning Solution Now Available in Countries Requiring CE Marking
British Heart Foundation Features Breakthrough Heart Attack Prevention Technology in Online News Programme for World Heart Day
CaRi-Heart® Users share Excitement on Potential for Heart Attack Prediction and Prevention
BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae
BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes for the detection of Group A Streptococcus, Mycoplasma pneumoniae and Flu A, Flu B, COVID-19 N1/RdRp. Xfree Flu A, Flu B, COVID-19 and Group A Streptococcus were previously CE-IVD marked while Mycoplasma pneumoniae is available as research use only. Laboratories can request custom manufactured formats for high-throughput use that may be validated for their intended use on a variety of real-time PCR platforms including, the BioGX pixl™, Applied Biosystems 7500, ThermoFisher QuantStudio and Bio-Rad CFX Touch.
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.
Bruker Launches de novo Sequencing for Immunopeptidomics, Library-Free dia-PASEF, Mass Dynamics Knowledge Visualization
PaSER™ Novor faster, real-time de novo sequencing for immunopeptidomics
Library-free dia-PASEF® analysis with PaSER 2023b proteomics software
Partnership with Mass Dynamics for 4D-Proteomics™ knowledge visualization
Allucent Expands Use of Medidata Clinical Cloud to Accelerate New Drug Development for Unmet Patient Needs
NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Systèmes company, today announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.
BPGbio announces appointments to its leadership team to accelerate research and commercialization
Anjan Thakurta, Ph.D., veteran Celgene/BMS Translational Medicine Expert Appointed CSO of BPGbio
Expands Commercial Team to Support Growth Strategy
Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
CHENGDU, China, Feb. 20, 2023 /PRNewswire/ — Recently, with the support of the National Key R&D Program of China, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell) approved by NMPA, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred to as “WestVac Biopharma (Guangzhou)”) has made significant progress on the development of the trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.
Tetracore Announces USDA Purchase of ASF and FMD Diagnostic Test Kits
ROCKVILLE, Md., Feb. 15, 2023 /PRNewswire/ — Tetracore, Inc. (Tetracore®) is pleased to announce its partnership with the United States Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) to provide a stock of PCR kits for both African Swine Fever (ASF) and Foot-and-Mouth Disease (FMD). These kits were purchased for use in the National Animal Vaccine and Veterinary Countermeasures Bank to ensure that the U.S. is prepared for a possible outbreak of a high-consequence Foreign Animal Disease (FAD). As the only USDA licensed PCR kits for these diseases, Tetracore’s VetAlert™ ASF and FMD Diagnostic Test kits will be critical in minimizing the potentially devastating impacts of a FAD outbreak.
EDX Medical Group Plc announces acquisition of Torax Biosciences Ltd
LONDON, Feb. 17, 2023 /PRNewswire/ — EDX Medical Group plc, (“EDX Medical” or the “Company”), which develops innovative digital diagnostic products and services for cancer, heart disease, neurology and infectious disease testing, today announces that it has acquired Torax Biosciences Ltd., a research company providing product development and pilot scale fabrication of immune-assays and diagnostic testing solutions.